Fortress Biotech, Inc.
NASDAQ:FBIO
2.08 (USD) • At close January 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 84.513 | 75.743 | 68.791 | 45.599 | 36.629 | 26.882 | 187.584 | 16.48 | 0.863 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 26.66 | 30.775 | 32.084 | 14.594 | 10.532 | 6.125 | 161.202 | 11.349 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 57.853 | 44.968 | 36.707 | 31.005 | 26.097 | 20.757 | 26.382 | 5.131 | 0.863 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.685 | 0.594 | 0.534 | 0.68 | 0.712 | 0.772 | 0.141 | 0.311 | 1 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 106.071 | 134.876 | 128.865 | 64.109 | 81.326 | 87.383 | 52.486 | 35.134 | 29.81 | 10.239 | 25.682 | 18.511 | 29.289 | 8.341 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 55.59 | 53.371 | 73.015 | 35.162 | 21.584 | 10.413 | 10.098 | 8.665 | 5.755 | 0.9 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 155.187 | 10.414 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 94.124 | 113.656 | 86.843 | 61.166 | 55.59 | 53.371 | 73.015 | 35.162 | 21.584 | 10.413 | 10.098 | 8.665 | 5.755 | 0.9 |
| Other Expenses
| 0 | -1.304 | 25.165 | 2.834 | 6.09 | 0.068 | -0.234 | -9.869 | 11.408 | 0 | 0 | 0 | 5.755 | 0.733 |
| Operating Expenses
| 200.195 | 247.228 | 215.708 | 125.275 | 136.916 | 140.754 | 127.59 | 70.841 | 51.394 | 20.652 | 35.78 | 27.176 | 35.044 | 9.241 |
| Operating Income
| -142.342 | -202.26 | -179.001 | -94.27 | -110.819 | -119.997 | -101.208 | -65.71 | -50.531 | -20.652 | -35.78 | -27.176 | -35.044 | -9.241 |
| Operating Income Ratio
| -1.684 | -2.67 | -2.602 | -2.067 | -3.025 | -4.464 | -0.54 | -3.987 | -58.553 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -11.291 | -9.9 | 24.188 | -8.579 | 9.159 | -10.803 | -7.717 | -5.58 | -3.352 | 0.266 | -1.378 | -0.434 | -1.316 | -0.741 |
| Income Before Tax
| -153.633 | -213.464 | -164.353 | -102.849 | -101.66 | -130.8 | -98.323 | -71.29 | -53.883 | -20.386 | -37.158 | -27.61 | -36.36 | -9.982 |
| Income Before Tax Ratio
| -1.818 | -2.818 | -2.389 | -2.256 | -2.775 | -4.866 | -0.524 | -4.326 | -62.437 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.521 | 0.449 | 0.473 | 0.136 | -49.851 | -0.463 | 1.513 | -12.505 | -3.997 | 1.315 | 0.525 | 0.233 | -0.091 | 1.046 |
| Net Income
| -60.637 | -213.913 | -164.826 | -102.985 | -51.809 | -84.147 | -66.876 | -55.095 | -48.428 | -20.386 | -37.158 | -27.61 | -36.36 | -9.982 |
| Net Income Ratio
| -0.717 | -2.824 | -2.396 | -2.258 | -1.414 | -3.13 | -0.357 | -3.343 | -56.116 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -8.47 | -36.1 | -30.26 | -21.45 | -14.2 | -29.04 | -24.08 | -20.68 | -18.56 | -8.42 | -18.32 | -19.12 | -4.74 | -1.69 |
| EPS Diluted
| -8.47 | -36.1 | -30.26 | -21.45 | -14.2 | -29.04 | -24.08 | -20.68 | -18.56 | -8.42 | -18.32 | -19.12 | -4.74 | -1.69 |
| EBITDA
| -133.643 | -190.469 | -142.254 | -87.82 | -85.157 | -118.401 | -88.566 | -66.871 | -52.373 | -20.629 | -35.763 | -27.176 | -35.044 | -8.447 |
| EBITDA Ratio
| -1.581 | -2.652 | -2.593 | -2.041 | -2.829 | -4.344 | -0.525 | -3.901 | -58.269 | 0 | 0 | 0 | 0 | 0 |